Treatment to slow early Alzheimer’s gets TGA approval As donanemab becomes available to Australian patients, experts warn the health system must be ready for the significant shift it could bring.
Semaglutide links to eye disorders in spotlight The TGA has received 44 reports linked to the drug, but one GP says a spike in concern may not be ‘mentioning high-quality evidence’.
TGA warns of ‘possible but rare’ RSV vaccines risk Product Information for Arexvy and Abrysvo has been updated to reflect a low risk of Guillain-Barre Syndrome following vaccination.
In Practice: Changes to dual-labelled medicine ingredient names The TGA has advised that more dual-labelled medicine ingredient names have begun the transition to sole ingredient names.
Further ADHD medication shortages GPs and patients have been warned to plan ahead, with Ritalin tablets already in shortage and further impacts on the way.
TGA strengthens warnings on antibiotic side effects GPs have been asked to use fluoroquinolones ‘judiciously’, as the Administration rolls out more prominent warnings.
Wegovy approved for cutting cardiovascular disease risk The TGA has approved semaglutide (sold as Wegovy) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in overweight and obese adults.
ADHD med shortages ‘a merry-go-round you just can’t predict’ The new school year has coincided with another series of shortages, forcing patients and prescribers to rethink their options.
‘A big difference’: Poisons Standard change brings hope Reduced paracetamol pack sizes are now in force, as a new report highlights the number of children hospitalised due to preventable medicine-related issues.
Most GPs discover medication shortages through patients: Poll A new survey highlights the urgency of improving measures to communicate supply chain disruptions, with patients increasingly feeling an impact.